PierianDx Announces the Appointment of Lindsay Mateo as CBO
St. LOUIS, MO., March 2, 2021 — PierianDx, the global leader in clinical genomics knowledge, today
announced the appointment of Lindsay Mateo as Chief Business Officer, effective immediately. In
her new role, Ms. Mateo will reinforce the company’s position as the leading provider of clinical
genomics solutions in the fight against cancer and hereditary disease. She will also head the
company’s life sciences efforts, establishing key alliances with industry partners and
biopharmaceutical companies that will ultimately provide broader access to genomic testing and
precision medicine-based treatments for patients.
Ms. Mateo is an experienced executive with a history of building world-class teams, devising
successful commercial strategies, and building partnerships within the diagnostics industry. Prior to
joining PierianDx, she served as Head of Commercial Operations and later as VP, Head of Life
Sciences at Tempus. She has also led commercial teams at NAVICAN, an Intermountain Healthcare
Company, focused on precision medicine, and Genoptix, now a NeoGenomics company.
“We are thrilled to welcome Lindsay to PierianDx in this exciting time of the company’s evolution and
growth,” says Mark McDonough, Chief Executive Officer, PierianDx. “Lindsay brings deep experience
in cancer diagnostics and life sciences, and she has an excellent track record helping emerging
companies scale. She will spearhead efforts to leverage our data assets and build out our
commercial strategy in engaging with industry partners and the biopharma market segment as the
company manifests its vision to democratize clinical genomics globally.”